Anmelden zur Ansicht der Organisations- und Vertragspreise.
Größe auswählen
Ansicht ändern
Über diesen Artikel
Empirische Formel (Hill-System):
C16H15N3OS
CAS-Nummer:
Molekulargewicht:
297.37
UNSPSC Code:
51111800
NACRES:
NA.77
MDL number:
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhaltenQuality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
SMILES string
S=C1Nc2c(cc(cc2)c3[n](c(cc3)C#N)C)C(O1)(C)C
InChI
1S/C16H15N3OS/c1-16(2)12-8-10(4-6-13(12)18-15(21)20-16)14-7-5-11(9-17)19(14)3/h4-8H,1-3H3,(H,18,21)
InChI key
PYVFWTPEBMRKSR-UHFFFAOYSA-N
Biochem/physiol Actions
Non-steroidal progesterone receptor agonist
Tanaproget is a high affinity, high efficacy and selective orally available non-steroidal progesterone receptor agonist.
signalword
Danger
hcodes
Hazard Classifications
Repr. 1B
Lagerklasse
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
Hier finden Sie alle aktuellen Versionen:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
Louis Allott et al.
EJNMMI radiopharmacy and chemistry, 4(1), 1-1 (2019-10-30)
The histological evaluation of estrogen receptor (ER) and progesterone receptor (PR) expression in breast cancer lesions from biopsy tissue can stratify patients to receive endocrine therapy. Furthermore, PR expression can predict response to selective estrogen receptor modulators (SERMs). Current immunohistochemical
Richard C Winneker et al.
Steroids, 73(7), 689-701 (2008-05-13)
Progesterone receptor (PR) modulators have evolved both structurally and mechanistically over the past half-century. Classical steroidal PR agonists continue to play an important role in women's health such as in oral contraception and post-menopausal hormone therapy whereas steroid-based PR antagonists
Jody L Bapst et al.
Contraception, 74(5), 414-418 (2006-10-19)
This study aimed to evaluate the pharmacokinetics, pharmacodynamics and safety of the nonsteroidal progesterone receptor agonist, tanaproget. A randomized, double-blind, placebo-controlled, sequential-group study of ascending single doses of tanaproget was conducted in healthy, 25- to 45-year-old women on cycle days
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SML2779-25MG | 04061841772491 |
| SML2779-5MG | 04061841772507 |
